Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: In vitro and in vivo studies

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 374-384

  Hu, Yanmin ^a   Coates, Anthony R M ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b c o Earlsfield Business Centre   (United Kingdom)

Author keywords

Antibiotic combinations; Enhancers; Mouse skin infection models; MRSA; S. Aureus; Topical agents

Indexed keywords

CHLORHEXIDINE; GENTAMICIN; HT 61; NEOMYCIN; PSEUDOMONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SKIN INFECTION; THERAPY EFFECT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 84872389940     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks384     Document Type: Article

References (52)

1. Fry DE, Barie PS. The changing face of Staphylococcus aureus: a continuing surgical challenge. Surg Infect (Larchmt) 2011; 12: 191-203.
2. Magret M, Lisboa T, Martin-Loeches I et al. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care 2011; 15: R62.
3. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63 SUPPL 1: S1-44.
4. Climo MW, Sepkowitz KA, Zuccotti G et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37: 1858-65.
5. Bertrand X, Slekovec C, Talon D. Use of mupirocin-chlorhexidine treatment to prevent Staphylococcus aureus surgical-site infections. Future Microbiol 2010; 5: 701-3.
6. Bode LG, Kluytmans JA, Wertheim HF et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9-17.
7. Edgeworth JD. Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. J Antimicrob Chemother 2011; 66 SUPPL 2: ii41-7.
8. Gilpin DF, Small S, Bakkshi S et al. Efficacy of a standard methicillin-resistant Staphylococcus aureus decolonisation protocol in routine clinical practice. J Hosp Infect 2010; 75: 93-8.
9. Kurup A, Chlebicka N, Tan KY et al. Active surveillance testing and decontamination strategies in intensive care units to reduce methicillin-resistant Staphylococcus aureus infections. Am J Infect Control 2010; 38: 361-7.
10. Ammerlaan HS, Kluytmans JA, Wertheim HF et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009; 48: 922-30.
11. Paterson DL, Rihs JD, Squier C et al. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-8.
12. Tuchscherr L, Medina E, Hussain M et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3: 129-41.
13. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-8.
14. Teo BW, Low SJ, Ding Y et al. High prevalence of mupirocin-resistant staphylococci in a dialysis unit where mupirocin and chlorhexidine are routinely used for prevention of catheter-related infections. J Med Microbiol 2011; 60: 865-7.
15. McNeil JC, Hulten KG, Kaplan SL et al. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob Agents Chemother 2011; 55: 2431-3.
16. Leigh DA, Joy G. Treatment of familial staphylococcal infection- comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemother 1993; 31: 909-17.
17. Pappas S, Nikolopoulos TP, Korres S et al. Topical antibiotic ear drops: are they safe? Int J Clin Pract 2006; 60: 1115-9.
18. Sattar SA, Farzana K, Hameed A. Resistance pattern of antibiotics against clinical isolates of Staphylococcus aureus. Pak J Pharm Sci 2005; 18: 18-22.
19. Walshe P, Rowley H, Timon C. A worrying development in the microbiology of otitis externa. Clin Otolaryngol Allied Sci 2001; 26: 218-20.
20. Hu Y, Shamaei-Tousi A, Liu Y et al. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS ONE 2010; 5: e11818.
21. Hurdle JG, O'Neill AJ, Chopra I et al. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9: 62-75.
22. Yoon J, Urban C, Terzian C et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753-7.
23. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010; 48: 3558-62.
24. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
25. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
26. Wu M, Hancock RE. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem 1999; 274: 29-35.
27. Kugelberg E, Norstrom T, Petersen TK et al. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 2005; 49: 3435-41.
28. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26: 220-3.
29. Aeschlimann JR, Dresser LD, Kaatz GW et al. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 335-40.
30. Chan EL, Zabransky RJ. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis 1987; 6: 157-64.
31. Firsov AA, Zinner SH, Vostrov SN et al. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50: 533-9.
32. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
33. Zhang Y, Wade MM, Scorpio A et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003; 52: 790-5.
34. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005; 5: 209-18.
35. van den Boogaard J, Kibiki GS, Kisanga ER et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-62.
36. Alou L, Cafini F, Sevillano D et al. In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin. Int J Antimicrob Agents 2004; 23: 513-6.
37. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677-83.
38. Arditi M, Yogev R. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother 1989; 33: 245-7.
39. Quiros Y, Vicente-Vicente L, Morales AI et al. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci 2011; 119: 245-56.
40. Mazurek B, Lou X, Olze H et al. In vitro protection of auditory hair cells by salicylate from the gentamicin-induced but not neomycin-induced cell loss. Neurosci Lett 2012; 506: 107-10.
41. Seguin MA, Vaden SL, Altier C et al. Persistent urinary tract infections and reinfections in 100 dogs (1989-1999). J Vet Intern Med 2003; 17: 622-31.
42. Coates AR, Hu Y. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs in R&D 2006; 7: 133-51.
43. Hu Y, Coates AR. Transposon mutagenesis identifies genes which control antimicrobial drug tolerance in stationary-phase Escherichia coli. FEMS Microbiol Lett 2005; 243: 117-24.
44. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
45. Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial resistance to antibiotics in infections of COPD patients. Curr Drug Targets 2011; 12: 521-30.
46. Wood AJ, Douglas RG. Pathogenesis and treatment of chronic rhinosinusitis. Postgrad Med J 2010; 86: 359-64.
47. Pechere JC, Hughes D, Kardas P et al. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007; 29: 245-53.
48. Hancock RE. Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells. J Antimicrob Chemother 1981; 8: 429-45.
49. Moellering RC Jr, Weinberg AN. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14C-labeled streptomycin by enterococci. J Clin Invest 1971; 50: 2580-4.
50. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-44.
51. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 1993; 175: 5798-805.
52. Kuyyakanond T, Quesnel LB. The mechanism of action of chlorhexidine. FEMS Microbiol Lett 1992; 79: 211-5.